Complete Filing Data
Bioquest Corp reported Net Income Loss of -$821.0 thousand for FY2022.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Bioquest Corp did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Net Income * | -$821.0K | -$2.3M | -$359.0K | -$616.2K | -$8.3K |
| Revenue * | $0.00 | $0.00 | |||
| General And Administrative Expense | $56.3K | $110.4K | $24.1K | $251.9K | $8.3K |
| Operating Income Loss | -$817.9K | -$2.2M | -$356.6K | -$251.9K | -$8.3K |
| Operating Expenses | $817.9K | $2.2M | $356.6K | ||
| Compensation Expense Excluding Cost Of Good And Service Sold | $467.6K | $1.4M | $164.0K | ||
| Interest Expense | $37.6K | $2.5K | |||
| Income Tax Expense Benefit | $0.00 | $0.00 | |||
| Income Taxes Paid Net | $0.00 | $0.00 | |||
| Selling And Marketing Expense | |||||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | |||||
| Cost Of Revenue | |||||
| Comprehensive Income Net Of Tax |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q1 2015 | Q4 2014 | Q3 2014 | Q1 2014 | Q4 2013 | Q3 2013 | Q1 2013 | Q4 2012 | Q3 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$123.4K | $50.1K | -$187.9K | -$437.0K | -$667.3K | -$630.3K | -$322.2K | -$194.8K | -$11.7K | -$18.2K | -$900.2K | -$892.2K | -$1.1M | $286.00 | -$3.3K | -$5.0K | -$2.4K | -$3.3K | -$259.00 |
| Revenue * | $1.2K | $29.8K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||
| General And Administrative Expense | $1.9K | -$5.4K | $35.3K | $16.0K | $43.9K | $15.4K | $39.6K | $6.2K | $876.3K | $729.6K | $1.1M | $1.2K | $3.3K | $5.0K | $2.4K | $3.3K | $259.00 | ||
| Operating Income Loss | -$49.7K | $52.7K | -$176.6K | -$464.1K | -$564.6K | -$629.2K | -$321.6K | -$194.8K | -$11.7K | -$901.0K | -$890.0K | -$1.2K | -$3.3K | -$5.0K | -$2.4K | -$3.3K | -$259.00 | ||
| Operating Expenses | $49.7K | -$52.7K | $176.6K | $464.1K | $564.6K | $629.2K | $321.6K | $194.8K | $11.7K | $1.2K | $3.3K | $2.4K | $3.3K | ||||||
| Compensation Expense Excluding Cost Of Good And Service Sold | $83.6K | $384.0K | $384.0K | $384.0K | $256.0K | $66.5K | |||||||||||||
| Interest Expense | $23.8K | $4.1K | $13.0K | $45.3K | $16.9K | $1.1K | $600.00 | ||||||||||||
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||||
| Income Taxes Paid Net | $0.00 | $0.00 | |||||||||||||||||
| Selling And Marketing Expense | $5.3K | $20.7K | $0.00 | $0.00 | |||||||||||||||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $3.5K | $987.00 | $0.00 | $0.00 | |||||||||||||||
| Cost Of Revenue | $20.5K | $169.6K | $0.00 | $0.00 | |||||||||||||||
| Comprehensive Income Net Of Tax | -$896.7K | -$891.2K | $286.00 | -$3.3K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 | FY2019 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity * | -$138.6K | -$8.8K | $9.0K | $2.7K | |||
| Cash And Cash Equivalents At Carrying Value | $260.00 | $166.00 | $946.00 | ||||
| Liabilities And Stockholders Equity | $17.1K | $166.00 | $9.1K | ||||
| Common Stock Value | $8.7K | $8.0K | $54.1K | ||||
| Assets | $17.1K | $166.00 | $9.1K | ||||
| Liabilities | $1.8M | $138.7K | $101.00 | ||||
| Assets Current | $17.1K | $166.00 | $8.0K | ||||
| Retained Earnings Accumulated Deficit | -$9.8M | -$7.5M | |||||
| Liabilities Current | $1.8M | $98.7K | $101.00 | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $166.00 | ||||||
| Additional Paid In Capital Common Stock | $8.1M | $7.3M | |||||
| Cash And Cash Equivalents Period Increase Decrease | $535.9K | $7.0K | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $33.3K | $94.00 | $166.00 | ||||
| Accounts Payable And Accrued Liabilities Current | $174.9K | $18.3K | |||||
| Debt Instrument Unamortized Discount Current | $0.00 | $24.1K | $24.1K | ||||
| Long Term Notes Payable | $30.8K | ||||||
| Interest Payable Current | $6.0K | $825.00 | |||||
| Derivative Liabilities Current | $138.6K | ||||||
| Property Plant And Equipment Net | $1.1K | ||||||
| Accounts Payable Current | $0.00 | ||||||
| Employee Related Liabilities Current | $1.4M | $70.0K | |||||
| Convertible Notes Payable Current | $74.2K | ||||||
| Other Liabilities | $0.00 | ||||||
| Deferred Finance Costs Net | |||||||
| Common Stock Shares Subscriptions | 0.00 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | |||||||
| Accrued Liabilities Current |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q2 2019 | Q1 2015 | Q4 2014 | Q3 2014 | Q2 2014 | Q1 2014 | Q4 2013 | Q3 2013 | Q2 2013 | Q1 2013 | Q4 2012 | Q3 2012 | Q2 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | -$536.4K | -$433.0K | -$393.6K | -$443.7K | -$2.1M | -$1.8M | -$1.4M | -$803.1K | -$360.8K | -$6.7K | -$11.7K | $5.1M | $4.6M | $4.8M | $875.2K | $1.0K | $725.00 | $4.0K | $9.0K | ||||||
| Cash And Cash Equivalents At Carrying Value | $15.0K | $33.5K | $116.00 | $818.00 | $2.7K | $60.00 | $70.00 | $310.9K | $401.2K | $848.0K | $543.9K | $452.00 | $4.00 | $3.1K | $8.0K | $10.2K | $12.5K | $14.4K | $0.00 | ||||||
| Liabilities And Stockholders Equity | $15.0K | $33.5K | $116.00 | $6.9K | $14.2K | $22.3K | $16.3K | $5.4M | $4.9M | $5.2M | $889.9K | $1.1K | $826.00 | $4.1K | |||||||||||
| Common Stock Value | $11.5K | $11.3K | $11.3K | $11.3K | $8.8K | $8.4K | $8.3K | $163.3K | $156.7K | $62.1K | $54.1K | $5.4K | $5.4K | $5.4K | |||||||||||
| Assets | $15.0K | $33.5K | $116.00 | $6.9K | $14.2K | $22.3K | $16.3K | $5.4M | $4.9M | $5.2M | $889.9K | $1.1K | $826.00 | $4.1K | |||||||||||
| Liabilities | $551.4K | $466.5K | $393.7K | $450.5K | $2.2M | $393.5K | $819.4K | $305.8K | $290.3K | $381.3K | $14.7K | $101.00 | $101.00 | ||||||||||||
| Assets Current | $15.0K | $33.5K | $116.00 | $6.9K | $14.2K | $22.3K | $16.3K | $1.9M | $1.4M | $1.3M | $889.9K | $452.00 | $4.00 | ||||||||||||
| Retained Earnings Accumulated Deficit | -$10.8M | -$10.7M | -$10.4M | -$10.5M | -$10.3M | -$393.6K | -$3.4M | -$2.5M | -$1.6M | -$498.5K | -$18.5K | -$18.8K | -$15.5K | -$10.5K | |||||||||||
| Liabilities Current | $551.4K | $466.5K | $393.7K | $450.5K | $2.2M | $1.4M | $779.4K | $305.8K | $290.3K | $361.3K | $14.7K | ||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $15.0K | $33.5K | $116.00 | $818.00 | $2.7K | $260.00 | $60.00 | $70.00 | $2.6K | $34.7K | $0.00 | ||||||||||||||
| Additional Paid In Capital Common Stock | $10.1M | $10.0M | $10.0M | $10.0M | $8.1M | $7.7M | $7.7M | $14.1K | $14.1K | $14.1K | $14.1K | ||||||||||||||
| Cash And Cash Equivalents Period Increase Decrease | $304.2K | -$4.9K | $13.5K | ||||||||||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$18.6K | $2.5K | $2.5K | ||||||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | $212.7K | $181.6K | $218.1K | $277.6K | $243.3K | $284.1K | $754.2K | ||||||||||||||||||
| Debt Instrument Unamortized Discount Current | $0.00 | $0.00 | $10.9K | $37.3K | $2.3K | ||||||||||||||||||||
| Long Term Notes Payable | $40.0K | $40.0K | |||||||||||||||||||||||
| Interest Payable Current | $19.3K | $15.5K | $14.2K | $10.1K | $8.1K | ||||||||||||||||||||
| Derivative Liabilities Current | $113.0K | $63.0K | $63.0K | $64.5K | $66.2K | $138.6K | |||||||||||||||||||
| Property Plant And Equipment Net | $26.8K | $32.2K | $19.8K | $0.00 | |||||||||||||||||||||
| Accounts Payable Current | $188.8K | $223.3K | $308.3K | $14.7K | |||||||||||||||||||||
| Employee Related Liabilities Current | $1.7M | $987.8K | |||||||||||||||||||||||
| Convertible Notes Payable Current | $183.3K | $183.3K | $40.0K | $40.0K | |||||||||||||||||||||
| Other Liabilities | $0.00 | $0.00 | $0.00 | ||||||||||||||||||||||
| Deferred Finance Costs Net | $0.00 | $0.00 | $252.2K | $128.2K | |||||||||||||||||||||
| Common Stock Shares Subscriptions | 459.9K | 5.9M | 1.5M | ||||||||||||||||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$8.5M | -$7.5M | $5.2K | $2.7K | -$81.4K | $0.00 | |||||||||||||||||||
| Accrued Liabilities Current | $76.4K | $26.4K | $43.4K | $0.00 | $0.00 | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Share-Based Compensation * | $206.7K | $530.0K | $117.3K | ||
| Financing Cash Flow * | $150.0K | $193.3K | $125.0K | $1.1M | $14.7K |
| Operating Cash Flow * | -$116.7K | -$193.2K | -$124.8K | -$600.3K | -$7.6K |
| Proceeds From Issuance Of Common Stock | $65.0K | $135.0K | $55.0K | $0.00 | $14.6K |
| Increase Decrease In Prepaid Expense | -$16.8K | -$12.6K | $0.00 | $0.00 | |
| Increase Decrease In Accounts Payable | $14.7K | $0.00 | |||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $6.7K | $156.6K | $36.5K | ||
| Increase Decrease In Accrued Liabilities | |||||
| Proceeds From Issuance Or Sale Of Equity | $1.5M | $0.00 | |||
| Net Cash Provided By Used In Investing Activities Continuing Operations | $0.00 | $0.00 | |||
| Increase Decrease In Employee Related Liabilities | $492.9K | $1.3M | $70.0K | ||
| Proceeds From Notes Payable | $85.0K | $58.3K | $40.0K | ||
| Increase Decrease In Due To Officers And Stockholders | $23.1K | $11.6K | $9.6K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2022 | Q4 2021 | Q3 2021 | Q4 2020 | Q3 2020 | Q3 2014 | Q3 2013 | Q3 2012 |
|---|---|---|---|---|---|---|---|---|
| Share-Based Compensation * | $16.7K | $150.0K | ||||||
| Financing Cash Flow * | $65.0K | $100.0K | $668.0K | $0.00 | $13.6K | |||
| Operating Cash Flow * | -$18.6K | -$62.5K | -$97.5K | -$363.8K | -$4.9K | -$97.00 | ||
| Proceeds From Issuance Of Common Stock | $65.0K | $100.0K | $0.00 | $13.6K | ||||
| Increase Decrease In Prepaid Expense | -$5.4K | $31.1K | $0.00 | |||||
| Increase Decrease In Accounts Payable | -$14.7K | $0.00 | ||||||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $31.1K | $68.4K | $22.9K | |||||
| Increase Decrease In Accrued Liabilities | $25.0K | $0.00 | ||||||
| Proceeds From Issuance Or Sale Of Equity | $1.2M | $0.00 | ||||||
| Net Cash Provided By Used In Investing Activities Continuing Operations | $35.00 | $0.00 | ||||||
| Increase Decrease In Employee Related Liabilities | $376.0K | $209.8K | ||||||
| Proceeds From Notes Payable | ||||||||
| Increase Decrease In Due To Officers And Stockholders | -$18.2K | -$8.6K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Diluted EPS * | -$0.09 | -$0.09 | -$0.01 | $0.00 | |
| Common Stock Shares Outstanding | 8.7M | 8.0M | 54.1M | ||
| Common Stock Shares Issued | 8.7M | 8.0M | 54.1M | ||
| Common Stock Shares Authorized | 500.0M | 500.0M | 75.0M | ||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | ||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 8.3M | 4.1M | 54.1M | 52.3M | |
| Weighted Average Number Of Shares Outstanding Basic | |||||
| Earnings Per Share Basic | $-0.08 | $-0.28 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q1 2015 | Q4 2014 | Q3 2014 | Q2 2014 | Q1 2014 | Q4 2013 | Q3 2013 | Q1 2013 | Q4 2012 | Q3 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | $0.00 | -$0.08 | -$0.08 | -$0.02 | -$0.05 | -$0.01 | -$0.01 | -$0.02 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| Common Stock Shares Outstanding | 11.5M | 11.3M | 11.3M | 11.3M | 8.8M | 8.4M | 8.3M | 454.3M | 163.3M | 156.7M | 62.1M | 54.1M | 5.4M | 5.4M | 5.4M | ||||||
| Common Stock Shares Issued | 11.5M | 11.3M | 11.3M | 11.3M | 8.8M | 8.4M | 8.3M | 163.3M | 156.7M | 62.1M | 54.1M | 5.4M | 5.4M | 5.4M | |||||||
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 75.0M | 75.0M | 75.0M | |||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 8.3M | 8.2M | 8.0M | 237.2K | 159.9M | 143.5M | 56.6M | 54.1M | 54.1M | 54.1M | 4.6M | ||||||||||
| Weighted Average Number Of Shares Outstanding Basic | 11.3M | 11.3M | 9.4M | 8.8M | 8.3M | 8.2M | 8.1M | 5.4M | 4.6M | ||||||||||||
| Earnings Per Share Basic | $-0.01 | $0.00 | $-0.02 | $-0.05 | $-0.08 | $-0.08 | $-0.04 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Professional Fees | $87.4K | $152.2K | $51.2K | ||
| Stock Issued During Period Value New Issues | $65.0K | $135.0K | $55.0K | $14.6K | |
| Prepaid Expense Current | $16.8K | ||||
| Stock Compensation Expense | $206.7K | $530.0K | $117.3K | ||
| Derivative Gain Loss On Derivative Net | $75.5K | -$85.8K | |||
| Depreciation | $648.00 | $648.00 | |||
| Other General Expense | |||||
| Legal Fees | |||||
| Interest Paid Net | $0.00 | $0.00 | |||
| Due To Officers Or Stockholders Current | $21.2K | $9.6K | |||
| Due From Related Parties Current | $0.00 | ||||
| Additional Paid In Capital | -$34.6K | ||||
| Foreign Currency Transaction Gain Loss Before Tax | |||||
| Costs And Expenses |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q1 2020 | Q4 2019 | Q1 2015 | Q4 2014 | Q3 2014 | Q2 2014 | Q1 2014 | Q4 2013 | Q3 2013 | Q2 2013 | Q1 2013 | Q4 2012 | Q3 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Professional Fees | $47.8K | $2.7K | $41.1K | $30.8K | $36.7K | $79.8K | $26.0K | $7.3K | $11.7K | ||||||||||||
| Stock Issued During Period Value New Issues | $65.0K | $15.0K | $20.0K | $100.0K | $55.0K | ||||||||||||||||
| Prepaid Expense Current | $6.0K | $11.4K | $22.2K | $16.2K | $887.4K | $400.7K | $131.1K | $0.00 | $0.00 | $0.00 | $0.00 | ||||||||||
| Stock Compensation Expense | -$50.0K | $33.3K | $100.0K | $150.0K | $114.8K | ||||||||||||||||
| Derivative Gain Loss On Derivative Net | -$50.0K | $1.5K | $1.7K | $72.4K | -$85.8K | ||||||||||||||||
| Depreciation | $0.00 | $162.00 | $162.00 | ||||||||||||||||||
| Other General Expense | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||||||||
| Legal Fees | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||||||||
| Interest Paid Net | $0.00 | $0.00 | |||||||||||||||||||
| Due To Officers Or Stockholders Current | $23.1K | $23.1K | $3.0K | ||||||||||||||||||
| Due From Related Parties Current | $320.7K | $195.9K | $0.00 | $346.1K | |||||||||||||||||
| Additional Paid In Capital | $6.9M | $6.5M | $757.4K | -$34.6K | |||||||||||||||||
| Foreign Currency Transaction Gain Loss Before Tax | $817.00 | -$2.2K | $0.00 | $0.00 | |||||||||||||||||
| Costs And Expenses | $902.1K | $919.9K | $1.2K | $3.3K |
Most recent annual filing with the SEC: August 15, 2022
Data sourced from SEC EDGAR public filings as of August 6, 2026.